Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9581-9590

  Martin Orozco, Natalia ^a   Li, Yufeng ^a   Wang, Yijun ^a   Liu, Shijuan ^a   Hwu, Patrick ^a   Liu, Yong Jun ^a   Dong, Chen ^a   Radvanyi, Laszlo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 2 RECEPTOR ALPHA; LIGAND; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CELL EXPANSION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; L CELLS (CELL LINE); LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 78649941232     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1379     Document Type: Article

References (40)

1. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol 2009;27:551-89.
2. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
3. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
4. +CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
5. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-99. (Pubitemid 37022112)
6. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
7. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJJ, Wunderlich JR, Merino MJ, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008;112:4953-60.
8. +CD25(high) regulatory T cells are over-represented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
9. + regulatory T cell proliferation. J Exp Med 2005;202:919-29.
10. +CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006;66:4488-95.
11. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007;104:20884-9.
12. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006;107:628-36. (Pubitemid 43076387)
13. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009;30:656-65.
14. + regulatory T cells suppress effector T cell proliferation. Clin Immunol 2005;115:3-9.
15. Haringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J Exp Med 2009;206:1009-17.
16. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001;409: 97-101. (Pubitemid 32098632)
17. Chen XL, Cao XD, Kang AJ, Wang KM, Su BS, Wang YL. In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. World J Gastroenterol 2003;9:1370-3.
18. Klingenberg R, Autschbach F, Gleissner C, Giese T, Wambsganss N, Sommer N, et al. Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro. Eur J Immunol 2005;35:1712-21. (Pubitemid 40862319)
19. Qian X, Agematsu K, Freeman GJ, Tagawa Y, Sugane K, Hayashi T. The ICOS-ligand B7-H2, expressed on human type II alveolar epithelial cells, plays a role in the pulmonary host defense system. Eur J Immunol 2006;36:906-18.
20. + T cell cytotoxicity. Brain 2004;127:1182-90.
21. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A, Melms A, et al. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia 2003;44:296-301. (Pubitemid 37484480)
22. + Th1 and Th2 cells. Nephron Exp Nephrol 2004;98:e31-8.
23. Wiendl H, Mitsdoerffer M, Schneider D, et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003;126:1026-35.
24. Khayyamian S, Hutloff A, Buchner K, Grafe M, Henn V, Kroczek RA, et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A. 2002;99:6198-203. (Pubitemid 34493289)
25. + T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004;199:1479-89.
26. + regulatory T cells in human thymus and periphery. Immunity 2008;28:870-80.
27. + T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008;180:2967-80.
28. Liang L, Porter EM, Sha WC. Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling. J Exp Med 2002;196:97-108. (Pubitemid 34747315)
29. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-98.
30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, , et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
31. Van Lier RA, Boot JH, De Groot ER, Aarden LA. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 1987;17:1599-604.
32. - T cells. J Clin Invest 2003;112:1437-43.
33. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006;103:6659-64.
34. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008;29:44-56.
35. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
36. Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002;13:1517-26. (Pubitemid 34579241)
37. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med.
38. + T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
39. + regulatory T cells. J Immunol 2004;172:5986-93.
40. Luczynski W, Wawrusiewicz-Kurylonek N, Stasiak-Barmuta A, Urban R, Ilendo E, Urban M, et al. Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes. Acta Biochim Pol 2009;56:361-70.